South Korean startup ILIAS Biologics has signed a Memorandum of Understanding (MoU) with HK inno.N for joint research to develop new biomedicine candidates.

With this MoU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.

The MoU raises expectations on the synergy of ILIAS's versatile exosome platform technologies with enormous expandability and HK inno.N's extensive new drug development know-how.

ILIAS Biologics has an exosome platform technology that can load a polymer drug in a free form inside the exosome and deliver it stably inside the target cell. It has related technology patents in five countries including the United States, Japan, and China, and has recently been approved for a phase 1 clinical trial in Australia for an exosome-based anti-inflammatory drug candidate.

HK Inno.N, another startup based in South Korea, plans to develop an exosome treatment for chronic diseases and acute respiratory infections, centered on the bio research center, and strengthen the new biopharmaceutical pipeline.